GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

被引：0
|
作者：
Olislagers, M. [1 ]
De Jong, F. C. [1 ]
Van Etten, V. M. J. [1 ]
Kan, T. W. [1 ]
Zuiverloon, T. C. M. [1 ]
机构：
[1] Erasmus MC, Dept Urol, Rotterdam, Netherlands
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0281
引用
收藏
页码：S405 / S406
页数：2
相关论文
共 50 条
  • [1] Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    Gschwend, J. E.
    Loriot, Y.
    Nishiyama, H.
    Redorta, J. P.
    Daneshmand, S.
    Hussain, S. A.
    Cutuli, H. J.
    Procopio, G.
    Guadalupi, V.
    Vasdev, N.
    Naini, V.
    Crow, L.
    Triantos, S.
    Baig, M.
    Steinberg, G.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 98 - 106
  • [2] Re: Erdafitinib in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    JOURNAL OF UROLOGY, 2024, 212 (05): : 779 - 779
  • [3] Re: Erdafitinib in BCG-treated High-risk Non-muscle- invasive Bladder Cancer
    Babjuk, Marko
    EUROPEAN UROLOGY, 2024, 86 (03) : 280 - 280
  • [4] HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS
    Craig, Calkins Daniel
    Facundo, Davaro
    Chris, Guske
    Richard, Sirard, III
    Roger, Li
    Scott, Gilbert
    Wade, Sexton
    Philippe E, Spiess
    Michael, Poch
    Alice, Yu
    Logan, Zemp
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S52 - S52
  • [5] Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study
    Burger, Maximilian
    van der Aa, Madelon N. M.
    van Oers, Johanna M. M.
    Brinkmann, Anke
    van der Kwast, Theodorus H.
    Steyerberg, Ewout C.
    Stoehr, Robert
    Kirkels, Wim J.
    Denzinger, Stefan
    Wild, Peter J.
    Wieland, Wolf F.
    Hofstaedter, Ferdinand
    Hartmann, Arndt
    Zwarthoff, Ellen C.
    EUROPEAN UROLOGY, 2008, 54 (04) : 835 - 844
  • [6] Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
    Eisner, Joel R.
    de Jong, Florus C.
    Shibata, Yoichiro
    Mayhew, Gregory M.
    Davison, James M.
    Carcione, Jenna
    Pappan, Kirk L.
    Thomas, Shibu
    Triantos, Spyros
    Santiago-Walker, Ademi
    Baig, Mahadi
    Milburn, Michael V.
    Beebe, Kirk D.
    Zuiverloon, Tahlita C. M.
    CLINICAL CANCER RESEARCH, 2024, 30 (23) : 5374 - 5384
  • [7] Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Nature Clinical Practice Urology, 2006, 3 : 398 - 399
  • [8] Treatment of high-risk, non-muscle-invasive bladder cancer
    Lerner, Seth P.
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (08): : 398 - 399
  • [9] Re: Erdafitinib in BCG-treated High-risk Non-muscleinvasive Bladder Cancer
    Duquesne, Igor
    de la Taille, Alexandre
    EUROPEAN UROLOGY, 2024, 85 (01) : 74 - 75
  • [10] Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.
    Meeks, Joshua
    Carneiro, Benedito A.
    Pai, Sachin Gopalkrishn
    Oberlin, Daniel
    Rademaker, Alfred
    Fedorchak, Kyle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345